P&T COMMITTEE MEETING: November 2018: The following drug classes/subclass and newly approved agents will be reviewed:
ACNE AGENTS - TOPICAL ACNE AND ROSACEA: Adapeline, Plixda
NARCOTIC ANALGESICS AND COMBINATIONS - N/A: Butalbital
HEMATOLOGICAL AGENTS - WHITE BLOOD CELL STIMULANTS: Fulphila
METABOLIC AGENTS-MISCELLANEOUS - N/A: Galafold
TARGETED IMMUNOMODULATORY BIOLOGICS - NON TUMOR NECROSIS FACTOR INHIBITORS: Ilumya
BETA BLOCKERS & HYDROCHLOROTHIAZIDE COMBINATIONS - N/A: Kapspargo Sprinkle
BINDERS-CHELATORS-ANTIDOTES-OVERDOSE-AGENTS- N/A: Lokelma
HEMATOLOGICAL AGENTS - PLATELETS: Mulpleta
ANTIBIOTICS - TETRACYCLINES: Okebo
LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - N/A: Orilissa
CYSTIC FIBROSIS AGENTS - N/A: Orkambi Granule
LAXATIVES-CATHARTICS-STOOL SOFTENERS - N/A: Plenvu
ANTIPERSPIRANTS - N/A: Qbrexza
ANTIRETROVIRALS - COMBINATIONS: Symtuza
CORTICOSTEROIDS-IMMUNE MODULATORS - HEREDITARY ANGIOEDEMA AGENTS: Takhzyro
ONCOLOGICAL AGENTS - ACUTE MYELOGENOUS LEUKEMIA: Tibsovo
RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein.
There is no pre-proposal teleconference. Rather, questions shall be submitted via e-mail to the Request for Quote (RFQ) Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4. Also, responses to Part 3.4 is required.
POCs: Part 2.3 of the RFQ.
For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD